Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis

ConclusionsWe found an increased risk of herpes zoster infection, and transient cardiovascular events among patients treated with sphingosine-1-phosphate modulators.Clinical Trial RegistrationPROSPERO CRD42020172575.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research